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I. INTRODUCTION 
Since 1984, the Food and Drug Administration (“FDA”) has 
approved over 8,000 generic drugs, which comprise approximately 
seventy-eight percent of currently filled prescriptions.1  The Drug 
Price Competition and Patent Term Restoration Act of 1984 (also 
known as the “Hatch-Waxman Act”) governs the approval of generic 
drugs.2  The Act provides an expedited approval process for generic 
drugs that have an identical Reference Listed Drug (“RLD”).  
Provided a generic drug is the “same” as its listed drug counterpart, 
its manufacturer is permitted to forgo clinical testing, on the 
condition that the drug maintains the same label as the listed drug.3  
“Sameness” requires the generic drug be the same as the brand-
name drug in “dosage form, safety, strength, route of 
administration, quality, performance characteristics and intended 
use.”4 Generic drug manufacturers have no authority to modify or 
update their own safety labels if they want to maintain their generic 
approval.5  The inability to independently update labels has led to 
issues concerning generic drug manufacturers’ liability for failure to 
warn of safety concerns, which have recently been addressed by the 
U.S. Supreme Court.6 
Congress began to combat these concerns with the enactment 
of the Generic Drug User Fee Amendments of 2012 (“GDUFA”).7  
The GDUFA recognizes the growth of the generic drug industry by 
expediting the approval process for generics, saving time and money 
 
 1  Fact Sheet: New User Fees for Generic Drugs Will Enhance American’s Access to 
Less Expensive Drugs and Generate Major Cost Savings, U.S. FOOD AND DRUG 
ADMINISTRATION, http://www.fda.gov/RegulatoryInformation/Legislation/ 
SignificantAmendmentstotheFDCAct/FDASIA/ucm310992.htm (last visited Mar. 24, 
2016). 
 2  See 21 U.S.C. 355(j) (1)-(2); see also, Drug Price Competition and Patent Term 
Restoration Act of 1984 (Hatch-Waxman Amendments) Before the S. Comm. on the 
Judiciary, (2003) (statement of Daniel E. Troy, Chief Counsel, U.S. Food and Drug 
Administration) available at http://www.fda.gov/newsevents/testimony/ 
ucm115033.htm. 
 3  Examining Concerns Regarding FDA’s Proposed Changes to Generic Drug Leveling 
Before the Energy and Commerce Subcomm. On Health, U.S. H.R., (2014) (statement of 
Ralph. G. Neas, President and CEO, The Generic Pharmaceutical Association).  
 4  Id. 
 5  Id. 
 6  Jennifer M. Thomas, FDA Proposes a Rule that Would Undercut Generic Drug 
Preemption, FDA L. BLOG (November 12, 2013, 6:58PM), 
http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2013/11/fda-proposes-a-
rule-that-would-undercut-generic-preemption.html.   
 7  Food and Drug Administration Safety and Innovation Act, Pub. L. No. 112-144, 
§908, 126 Stat. 993 (2012). 
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for the industry, and ensuring Americans have access to low cost, 
quality medicine.8  In exchange for faster approval times, the generic 
industry must pay user fees, as branded pharmaceutical drugs are 
required to do.9  The GDUFA may be considered the beginning of 
major reform for the generic drug industry, placing some of the 
same obligations and benefits on the generic industry that the 
brand-name manufacturers have dealt with for years. 
The growth of the generic industry and the issues presented in 
recent Supreme Court cases have prompted the FDA to reconsider 
the current federal mandate and to suggest that generic drug 
manufacturers be permitted to update safety labels in response to 
safety issues that have been discovered.10  The proposed regulation 
would require generic drug makers to update their labels in light of 
newly acquired safety information to avoid injury to consumers, 
which could result in legal liability.11  This Note argues that allowing 
generic drug makers to update safety labels as soon as new 
information is received will increase patient safety and prevent 
injuries by providing timely updates to safety information.12  This 
would also allow generic drugs that no longer have a brand-name 
counterpart to update their labels.13 
These changes may also have an impact on manufacturer’s 
exposure to failure-to-warn liability.  Under the Supreme Court’s 
2011 ruling in PLIVA v. Mensing, generic drug makers are unable to 
add new side effect and safety information to product labeling and 
therefore should not be held accountable for any failure-to-warn 
claims.14  Currently, access to the courts depends on whether an 
individual has been prescribed a brand-name or generic drug.15  Dr. 
 
 8  Fact Sheet, supra note 1. 
 9  Fact Sheet, supra note 1 
 10  Joe Carlson, FDA’s Generic-Drug Label Rule Draws Controversy, MODERN 
HEALTHCARE (June 28, 2014), http://www.modernhealthcare.com/article/20140628/ 
MAGAZINE/306289979. 
 11  Id. 
 12  Id. 
 13  Id. 
 14  PLIVA, Inc. v. Mensing, 131 S. Ct. 2567 (2011); Ed Silverman, How Fast Should a 
Generic Drug Maker Update Labeling with New Safety Info? THE W.S.J. PHARMALOT, (Sept. 
3, 2014, 8:59AM), http://blogs.wsj.com/pharmalot/2014/09/03/how-fast-should-a-
generic-drug-maker-update-labeling-with-new-safety-info/; see also Mutual Pharm. Co. 
v. Bartlett, 133 S. Ct. 2466 (2013). 
 15  Examining Concerns Regarding FDA’s Proposed Changes to Generic Drug Labeling 
Before S. Comm. On Health, Comm. On Energy and Commerce, U.S. H.R., (2014) 
(statement of Janet Woodcock, Director, Center for Drug Evaluation and Research, 
Food and Drug Administration, Department of Health and Human Service) available 
at http://www.fda.gov/NewsEvents/Testimony/ucm389606.htm. 
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Janet Woodcock, Director of the Center for Drug Evaluation and 
Research at the Food and Drug Administration stated that if the 
proposed regulatory change is approved, it would allow consumers 
to file failure-to-warn claims against generic drug manufacturers.16  
Once generic drug makers have the right to change their label, they 
would be responsible for knowing the full effects of the drugs they 
produce, and may be sued for failing to update their labels in a 
timely fashion.17  The FDA notice of the proposed rule 
acknowledges that the proposed regulation may also change generic 
drug manufacturer’s liability.18  Although the proposed regulations 
may have a significant impact on generic drug makers’ liability, such 
discussion is beyond the scope of this Note. 
Part II of this Note will introduce background legislation and 
regulations concerning the labeling of brand-name and generic 
drugs.  It will describe the subsequent amendments to food and 
drug legislation in response to the growth of generic drugs over the 
past few decades.  Part II will also introduce the 2013 proposed 
regulatory amendments, which would provide generic 
manufacturers the ability to independently update safety labels.  
Part III of this Note will discuss the benefits of independent label 
changes to public policy and patient safety while keeping costs 
significantly lower than brand-name counterparts. 
II. BACKGROUND/OVERVIEW 
A. Statutory Background 
The Federal Food, Drug, and Cosmetic Act (“FDCA”) and the 
Public Health Service Act (“PHSA”), “[p]rovide [the] FDA with 
authority over the labeling for drugs and biological products.”19  The 
Acts also authorize the FDA to “enact regulations to facilitate the 
review and approval of applications regarding the labeling for those 
products.”20  Section 502(f) of the FDCA states that “a product is 
misbranded unless its labeling bears adequate directions for use, 
including adequate warnings against, among other things, unsafe 
dosage, methods, duration of administration, or application.”21  
 
 16  Id. 
 17  Carlson, supra note 10.  
 18  Ezra Friedman & Abraham L. Wickelgren, Who (if Anyone) Should be Liable for 
Injuries from Generic Drugs? NORTHWESTERN LAW & ECON RESEARCH PAPER NO. 14-19 (Oct. 
13, 2014) (citing 67986 Federal Register, Vol 78, No. 219, November 13, 2013). 
 19  See 21 U.S.C. § 301 (2016); see also 42 U.S.C. § 201 (2016). 
 20  Woodcock, supra note 15. 
 21  Woodcock, supra note 15. 
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According to Section 502(j) of the FDCA, “a product is misbranded 
if it is dangerous to health when used in the manner prescribed, 
recommended, or suggested in its labeling.”22  These statutory 
provisions created new standards for drug manufacturer’s products 
and facilities. 
In 1984, the FDCA was amended to include the Drug 
Competition and Patent Term Restoration Act, more commonly 
known as The Hatch-Waxman Act.23  The Hatch-Waxman Act 
provided a less stringent approval process for generic drug makers.  
The generic manufacturer is now required to submit an abbreviated 
new drug application, showing the generic drug is the “same” as a 
previously approved brand-name drug, and the generic is 
“bioequivalent” to the brand-name drug.24  Under the “sameness” 
requirement, the generic manufacturer must show that the generic 
drug meets the same standards of safety and efficacy, by proving that 
the generic drug has the same active ingredient, is identical in 
strength, dosage and administration, and has the same safety label.25  
The Hatch-Waxman Act exempted generic manufacturers from the 
“expensive, time-consuming, and ultimately repetitive clinical 
testing and trials that already had been performed on the innovator 
drug.”26  In the twenty-two years preceding the Act, only fifteen 
generics had been approved by the FDA.27  One year after the Act, 
more than 1,000 drugs were submitted for approval to the FDA.28  
Hatch-Waxman has resulted in billions of dollars of savings to the 
health care industry and consumers.29 
Currently, for most substantive changes to drug labeling, a 
brand-name manufacturer must submit an approval supplement 
and obtain FDA approval of the proposed labeling modification.30  
FDA regulations also require manufacturers of pharmaceutical and 
biological products to submit reports of adverse drug experiences 
 
 22  Woodcock, supra note 15. 
 23  Brian Wolfman & Anne King, Mutual Pharmaceutical Co. v. Bartlett and Its 
Implications, U.S.L.W. (Sept. 19, 2014), available at http://scholarship.law.georgetown. 
edu/facpub/1297. 
 24  Id. 
 25  Neas, supra note 3. 
 26  Neas, supra note 3. 
 27  Neas, supra note 3. 
 28  Neas, supra note 3. 
 29  Neas, supra note 3. 
 30  Supplemental Applications Proposing Labeling Changes for Approved Drugs 
and Biological Products, 78 Fed. Register 67985 (proposed Nov. 13, 2013), available at 
https://www.federalregister.gov/articles/2013/11/13/2013-26799/supplemental-
applications-proposing-labeling-changes-for-approved-drugs-and-biological-products. 
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that occur after approval.31  In the interest of public health, the 
FDCA permits certain labeling changes based on newly acquired 
safety information about the drug when the manufacturer submits 
a “changes being effected” (“CBE-0”) supplement describing the 
change.32  Newly acquired safety information is defined by the 
FDCA as, “. . .information derived from a clinical trial, an adverse 
event report, a post approval study . . .  peer reviewed biomedical 
literature, data derived from the post-market risk identification and 
analysis system under section 505(k); or other scientific data 
deemed appropriate by [the FDA].”33  When this information is 
received, the brand drug must update their warnings labels to reflect 
the new information.34 
The CBE-0 supplement regulations, “. . .allow application 
holders to comply with the requirement to update labeling 
promptly to include a warning about a clinically significant hazard 
as soon as there is reasonable evidence of a causal association with 
a drug . . . .”35  According to the 2008 amended regulations 
governing the CBE-0 process, a CBE-0 labeling supplement is only 
appropriate to show new information.36  The 2008 amendments 
clarified that the supplement may be used to “add or strengthen a 
contraindication, warning, precaution, or adverse reaction only if 
there is sufficient evidence of a causal association with the approved 
product.”37  The FDA reviews all labeling changes proposed in a 
CBE-0 supplement and the underlying data and research supporting 
the change.38  The FDA then accepts, rejects, or requests 
modifications to the proposed changes as deemed appropriate, and 
can bring enforcement action if the information makes the 
product’s label false or misleading.39  If the newly acquired 
information brings to light that the product no longer meets FDA 
standards, the agency may choose to rescind the drug’s approval.40 
 
 31  Id. 
 32  Id.; See also 21 C.F.R. § 314.70(c) (6) (iii); 21 C.F.R. § 601.12(f) (1). 
 33  See 21 U.S.C. § 505(o)(2)(C). 
 34  See 21 U.S.C. § 505(o) (2) (C). 
 35  See 78 Fed. Register 67985; see also 21 C.F.R. § 201.57(c). 
 36  Supplemental Applications Proposing Labeling Changes for Approved Drugs 
and Biological Products, 78 Fed. Register 67985-02 (proposed Nov. 13, 2013) (to be 
codified at 21 C.F.R. pt. 314 and 601) available at https://www.federalregister.gov 
/articles/2013/11/13/2013-26799/supplemental-applications-proposing-labeling-
changes-for-approved-drugs-and-biological-products.  
 37  Id. 
 38  Id. 
 39  See 21 U.S.C. § 352(a). 
 40  See 21 U.S.C. §§ 355(e), 355-1. 
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B. The 2012 Enactment of FDASIA/GDUFA: Paving the Way for 
Generic Label Updating 
In 2010, seventy-eight percent of pharmaceutical prescriptions 
were filled with generic brands.41  Today, the top ten drugs filled in 
America are all generic brands.42  Over the past decade, generic drugs 
have provided a savings of over $824 billion dollars to the nation’s 
health care system.43  In response to the rapid growth of generic 
drugs over the past decades, Congress, in 2012, enacted the Generic 
Drug User Fee Act (“GDUFA”) as a part of the Food and Drugs 
Administration Safety and Innovation Act (“FDASIA”).44  GDUFA 
allows for more speed in approving generic drugs while ensuring 
safety and low costs by requiring generic manufacturers to pay fees 
to supplement the costs of reviewing generic drug applications and 
inspecting facilities.45  As the FDA has explained, “[r]ecognizing the 
critical role generic drugs play in providing more affordable, 
therapeutically equivalent medicine, the Generic Drug User Fee 
program is designed to keep individual fee amounts as low as 
possible to supplement appropriated funding to ensure that 
consumers continue to receive the significant benefits offered by 
generic drugs. . .”46 
The FDASIA gives the FDA the authority to collect user fees 
from the pharmaceutical industry to “fund reviews of innovator 
drugs, medical devices, generic drugs and biosimiliar biological 
products.”47  The FDASIA also encourages innovation by providing 
a “breakthrough therapy” designation for certain drugs that may be 
 
 41  Gary Gatyas, IMS Institute Reports U.S. Spending on Medicines Grew 2.3 Percent in 
2010, to $307.4 Billion, IMS HEALTH (April 19, 2011), http://www.imshealth.com 
/en/about-us/news/ims-institute-reports-u.s.-spending-on-medicines-grew-2.3-
percent-in-2010,-to-$307.4-billion.  
 42  Karen von Koeckritz, Generic Drug Trends- What’s Next? (April 11, 2012), 
http://www.pharmacytimes.com/publications/issue/2012/April2012/Generic-Drug-
Trends-Whats-Next. 
 43  Generic Drug User Fee Act Program Performance Goals and Procedures, (Nov. 10, 
2014), available at http://www.fda.gov/downloads/ForIndustry/UserFees/GenericDrug 
UserFees/UCM282505.pdf. 
 44  Fact Sheet, supra note 1. 
 45  Generic Drug User Fee Amendments of 2012, U.S. Food and Drug Administration, 
(Nov. 10, 2014), available at http://www.fda.gov/ForIndustry/UserFees/Generic 
DrugUserFees/default.htm; See 112 H.R. 3988, 112th Cong. (2012). 
 46  Generic Drug User Fee Act Program Performance Goals and Procedures, supra note 
43. 
 47  Food and Drug Administration Safety and Innovation Act (FDASIA), U.S. Food and 
Drug Administration (Jan. 1, 2015), available at https://www.gpo.gov/fdsys/pkg/PLAW-
112publ144/pdf/PLAW-112publ144.pdf. 
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substantially superior to current drugs on the market.48  This 
designation would allow for an expedited review and approval 
process through the collection of fees to create additional 
resources.49  The FDASIA protects the drug supply chain and ensures 
patients have access to drugs they need by extending the FDA’s 
detention authority and increasing penalties for adulterated and 
counterfeit drugs.50 
The purpose of the GDUFA is to increase safety by requiring 
that any manufacturer who participates in the U.S. generic drug 
industry is inspected biennially.51  It also will “deliver greater 
predictability and timeliness to the review of generic drug 
applications, slashing review times and saving industry time and 
money.”52  The GDUFA also requires that any domestic or 
international facility involved in the manufacture of generic drugs 
and their ingredients be identified upon their sale in the United 
States to increase transparency in the complex, global 
pharmaceutical market.53  All facilities and companies selling 
generic drugs must register annually with the FDA.54  This includes 
manufacturers of active pharmaceutical ingredients whose products 
may be used in US products through another manufacturer or 
facility that repackages generic drugs.55  The FDA has laid out 
guidance on which companies need to self-identify and what 
information they are required to provide to the FDA.56  In its 
guidance documents, the FDA explained that “[t]he information 
provided through self-identification will enable quick, accurate and 
reliable surveillance of generic drugs and facilitate inspections and 
compliance.”57 
The GDUFA also aims to cut down the review time of generic 
drug applications from thirty-one months to about ten months.58  
 
 48  Id. 
 49  Id. 
 50  Id. 
 51  Generic Drug User Fee Act Program Performance Goals and Procedures, supra note 
43. 
 52  Fact Sheet, supra note 1. 
 53  Fact Sheet, supra note 1. 
 54  H.R. 3988, 112th Cong. (2012); see also Alexander Gaffney, FDA Releases 
Guidance on Facility Registrations, Payment Under GDUFA, Regulatory Affairs 
Professionals Society (Jan. 21, 2015), http://www.raps.org/regulatoryDetail.aspx?id 
=7435. 
 55  Id. 
 56  Id. 
 57  Id. 
 58  Thomas Sullivan, The Food and Drug Administration Safety and Innovation Act 
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The funds collected from the user fees, which is stated to be one half 
of one percent of generic drug sales, will be used to assess the safety 
of generic drugs.59 
The user fees result in benefits to the public health by financing 
the FDA to carry out functions that it could not do previously.60  By 
cutting the review time of a generic drug application, the GDUFA 
will increase savings in development time, while decreasing the 
costs of bringing a generic drug to the market.61  Therefore, this may 
also result in a decline in costs to consumers.62 
C. Recent Supreme Court Cases 
Recent Supreme Court cases have addressed the issue of 
whether generic drug manufacturers should be liable for failing to 
provide adequate warnings on drug labels.63  This wave of lawsuits 
began with Wyeth v. Levine in 2009.64 
In Wyeth, the patient was injured by using a brand-name anti-
nausea drug through an IV-push method.65  The patient claimed the 
drug’s label was defective because it failed to instruct clinicians to 
use an IV-drip method, rather than the higher-risk push method.66  
The patient filed a failure-to-warn suit in state court against the drug 
manufacturer, Wyeth, for failing to update the product’s label with 
newly acquired safety information, even though the labels 
conformed to FDA regulations.67 
The Supreme Court determined that federal law does not 
preempt a state law failure to warn claim that a brand-name drug’s 
 
(FDASIA): Summary of GDUFA, MDUFA, BsUFA and Pediatrics, Policy and Medicine 
(Nov. 10, 2014), http://www.policymed.com/2012/07/the-food-and-drug-
administration-safety-and-innovation-act-fdasia-summary-of-gdufa-mdufa-
bsufa.html. 
 59  Id. 
 60  Supplemental Applications Proposing Labeling Changes for Approved Drugs 
and Biological Products, supra note 30. 
 61  Supplemental Applications Proposing Labeling Changes for Approved Drugs 
and Biological Products, supra note 30. 
 62  Supplemental Applications Proposing Labeling Changes for Approved Drugs 
and Biological Products, supra note 30. 
 63  Woodcock, supra note 15. 
 64  Wyeth v. Levine, 555 U.S. 555 (2009). 
 65  See Wyeth, 555 U.S. at 559; see also Marie Boyd, Unequal Protection Under the Law: 
Why FDA Should Use Negotiated Rulemaking to Reform the Regulation of Generic Drugs, 35 
CARDOZO L. REV. 1525, 1530 (2014). 
 66  Id. 
 67  Jacob Goldstein, Wyeth v. Levine: The Mother of All Preemption Cases, W.S.J. BLOGS 
(Sept. 19, 2008, 8:21AM), http://blogs.wsj.com/health/2008/09/19/wyeth-v-levine-
the-mother-of-all-preemption-cases. 
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label did not contain an adequate warning.68  The Court explained 
that “[i]t has remained a central premise of federal drug regulation 
that the manufacturer bears responsibility for the contents of its 
label at all times.”69  The court held that the manufacturer must 
create an adequate safety label and ensure it is up to date as long as 
the product is being sold.70  The Court opined “Wyeth failed to 
demonstrate that it was impossible for it to comply with both 
federal and state requirements . . . the mere fact that the FDA 
approved . . . [the] label does not establish that it would have 
prohibited such a change.”71  The Court held that Wyeth could have 
strengthened the warning labels under the FDA’s CBE-0 regulation 
to comply with state law.72  The Court’s holding in Wyeth sent a clear 
message to brand-name drug manufacturers that “if they do not 
unilaterally strengthen their labels when they know it is necessary, 
they will face liability in the state court system.”73 
In 2011, the Supreme Court distinguished Wyeth in the 
subsequent case PLIVA Inc. v. Mensing.74  In PLIVA, the patients 
alleged they developed tardive dyskinesia after using the generic 
drug metoclopramide.75  The patients claimed the generic drug label 
did not contain adequate warnings of this adverse side effect.76  The 
manufacturer of the drug argued that: “(1) FDA regulations require 
the warnings on generic pharmaceuticals to be the same as those of 
the brand-name product; and (2) they had no ability to unilaterally 
add or strengthen warnings without FDA approval.”77  The Court 
agreed with the manufacturer and held the claim was preempted 
because generic manufacturers cannot add further warnings without 
violating FDA regulations under the Hatch-Waxman Act.78 
 
 
 68  Woodcock, supra note 15. 
 69  Wyeth, 555 U.S. at 570-71. 
 70  Id. 
 71  Wyeth, 555 U.S. at 573. 
 72  Boyd, supra note 65, at 1530. 
 73  Sarah S. James, Generic Drug Manufacturer Liability: Achieving a Balance Between 
Consumer Affordability and Safety, 38 IOWA J. CORP. L. 177, 182 (2013). 
 74  PLIVA, Inc. v. Mensing, 131 S. Ct. 2567 at 2581. 
 75  Id. at 2573. 
 76  Id. at 2569; Beth S. Rose, Charles J. Falletta & Vincent R. Lodato, Pliva, Inc. v. 
Mensing - United States Supreme Court Holds That Failure To Warn Claims Against Generic 
Pharmaceutical Manufacturers Are Pre-Empted By Federal Law, NAT’L L. J., Nov. 10, 2014, 
http://www.natlawreview.com/article/pliva-inc-v-mensing-united-states-supreme-
court-holds-failure-to-warn-claims-against-generic. 
 77  Rose et al., supra note 76. 
 78  Rose et al., supra note 76. 
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The holdings in Wyeth and PLIVA suggest “the Supreme Court 
has determined that generic manufacturer’s lack of independence 
with respect to drug safety labeling makes it impossible for them to 
comply with both Federal drug labeling requirements, and state tort 
law (failure-to-warn or design-defect) requirements.”79  The 
Supreme Court’s holdings in both cases suggests that access to the 
courts depends on whether a consumer purchased a generic or a 
brand-name drug.80 
In 2013, the Supreme Court decided Mutual Pharmaceutical Co. 
v. Bartlett.81  In Bartlett, the plaintiff suffered an adverse effect from 
taking the generic medication Sundilac.82  The patient, who took the 
prescribed medication to alleviate muscle pain, developed Stevens - 
Johnson syndrome and toxic epidermal necrolysis and became 
disfigured as a result.83  This side effect was originally listed as “a 
possible adverse reaction” on the safety label and was later moved 
to the “warnings” section of the generic label in conformance with 
the FDA’s recommendation.84 
The Supreme Court held in Bartlett that federal law preempts a 
state-law design-defect claim against a generic drug manufacturer 
under PLIVA.85  The Court first decided that New Hampshire does 
not have a “pure” design-defect cause of action, which would 
require a jury to balance the risks and benefits of an FDA approved 
drug to determine if it is “unreasonably dangerous.”86  As the FDA 
argued in its brief, this would undermine their assurance of 
approved drugs on a state-by-state and case-by-case basis, as well as 
Congress’ purpose that FDA approvals are made by experts applying 
science based judgment.87  The Supreme Court determined that New 
Hampshire’s design-defect cause of action includes an evaluation of 
the adequacy of the label.88  Through the design-defect analysis, the 
Court determined that generic drug manufacturers should not be 
held accountable for failure-to-warn or design-defect claims because 
generic drug makers are not permitted to independently update 
 
 79  Thomas, supra note 6. 
 80  Woodcock, supra note 15. 
 81  See Bartlett, 133 S. Ct. at 2494. 
 82  Id. at 2472. 
 83  Id. 
 84  Wolfman, supra note 23. 
 85  Bartlett, 133 S. Ct. at 2476; Wolfman, supra note 23. 
 86  Bartlett, 133 S. Ct. at 2470. 
 87  Id.; Brief for the United States as Amicus Curiae at 25, Mutual Pharm. Co. v. 
Bartlett, 133 S. Ct. 2466 (2013). 
 88  See Bartlett, 133 S. Ct. at 2470. 
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safety information on drug labeling.89 
Recently, a case has been decided by California’s highest court 
that contests the issue of generic drug liability.90  Here, the plaintiff 
was injured from her prolonged use of a generic form of Fosamax.91  
She claimed that Teva, the generic manufacturer, failed to update 
their warnings in compliance with the brand Fosamax’s warnings.92  
The defense rebutted that the plaintiff’s claim was preempted by 
PLIVA.  The trial court held, and the appellate court affirmed, that 
since the brand-name drug maker made the safety update, the 
generics were at fault for failing to immediately update their labels 
to conform to the newly acquired information.93  This case raised 
issues about the scope of PLIVA and whether failure-to-update 
claims would be preempted by federal law.94  The California 
Supreme Court declined to review the decision, therefore the 
pharmaceutical company appealed to the United States Supreme 
Court.95  The subsequent petition was denied, leaving the decision 
about generic drug liability to the FDA.96  The Supreme Court’s 
denial of the petition to hear this case may pave the way for similar 
failure to warn claims to be brought against generic drug makers in 
state court.97 
Similarly, the Alabama Supreme Court recently upheld a suit 
against brand-name manufacturer for damages caused by the 
generic form under the concept of “innovator liability.”98  Here, the 
court found brand drugs could be liable because the generic 
manufacturers relied on the warnings and labels of the brand drug.99  
 
 89  Ed Silverman, Lawmakers Ask White House to Review FDA Rule for Generic Label 
Changes, PHARMALOT (Sept. 2, 2014), http://blogs.wsj.com/pharmalot/2014/06/26/ 
lawmakers-ask-white-house-to-review-fda-rule-for-generic-label-changes/. 
 90  Teva Pharm. USA, Inc. v. Superior Court, 217 Cal. App. 4th 96 (Cal. App. 4th 
Dist. 2013). 
 91  Id. 
 92  Id. at 101. 
 93  Ed Silverman, Supreme Court Declines to Review Case About Generic Labeling, 
PHARMALOT (Jan. 21, 2015), http://blogs.wsj.com/pharmalot/2015/01/21/supreme-
court-declines-to-review-case-about-generic-labeling/. 
 94  Id. 
 95  Id. 
 96  Id.; see Teva Pharm. USA, Inc. v. Superior Court, 135 S.Ct. 831 (2015). 
 97  Kang, Y. Peter, High Court Lets Teva Drug Labeling Suit Go Ahead, LAW 360 (Jan. 
20, 2015), http://www.law360.com/articles/612895/high-court-lets-teva-drug-
labeling-suit-go-ahead. 
 98  See Weeks v. Wyeth, Inc., No. 1101397, slip op. at 65 (Ala. Aug. 15, 2014). 
 99  James W. Huston, Erin M. Bosman, and Julie Y. Park.  Weeks II: Innovator Liability 
Finds a Sweet Home in Alabama, CLIENT ALERT 1 (Aug. 20, 2014), 
http://www.mofo.com/~/media/files/clientalert/2014/08/140820weeksIIInnovatorlia
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The court relied on the holding in PLIVA, finding that the federal 
regulatory scheme made it foreseeable that the brand-name drug 
owed the generic version a duty of care.100  The pharmaceutical 
industry fears that this precedent could cause a damaging trend 
throughout the U.S. economy.101 
D. Proposed FDA Regulation 
Under the current federal regulations, a generic drug 
manufacturer may only use the CBE-0 supplement process to update 
its product labeling to conform to the approved safety label for the 
similar brand-name drug.102  A generic drug manufacturer may not 
independently file a CBE-0 supplement to the FDA in light of newly 
acquired safety information, nor unilaterally change its product’s 
label to add information that is different from the brand-name 
drug’s label.103 
On November 13, 2013, the FDA proposed to add 21 C.F.R. 
314.70(c)(8), which amends the current regulations and procedures 
that govern the ability to update and change generic drug safety 
labels.104  This proposed rule would allow generic drug 
manufacturers to independently submit “changes being effected” 
(“CBE-0”) supplements to update labels in light of newly acquired 
safety information, regardless of whether this information may 
differ from the warnings on the brand-name drug.105  The generic 
manufacturer would be able to distribute updated safety labels after 
submitting a CBE-0 to the FDA, as well as safety information 
supporting the change.106  The CBE-0 will also notify the maker of 
the listed drug of the newly acquired safety information.107 
To make updated safety information readily available to the 
public and to avoid confusion, the FDA proposed establishing a 
webpage where the FDA will post new safety information acquired 
from the CBE-0 supplements.108 
 
bility.pdf. 
 100  Id. 
 101  The Threat of ‘Innovator Liability’, WALL ST. J. (March 13, 2013), available at 
http://www.wsj.com/articles/SB10001424127887323628804578346231780434760 
 102  See 21 U.S.C. § 355(j) (1)-(2). 
 103  Id. 
 104  21 C.F.R. § 314.70(c)(8); Supplemental Applications Proposing Labeling 
Changes for Approved Drugs and Biological Products, supra note 30. 
 105  21 C.F.R. § 314.70(c)(8). 
 106  Id. 
 107  Id. 
 108  Id. 
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This proposed rule would allow a generic drug to display a label 
that is temporarily inconsistent with the labels of the listed drug.109  
The FDA would then evaluate whether the change is justified and 
make a decision on the generic and listed drug change at the same 
time, and as a result, both drugs will have the same FDA approved 
label.110  After the FDA approves the safety label change, there will 
be a thirty day time frame in which all drug manufacturers of the 
“same” drug will have to submit a CBE-0 supplement with 
conforming label changes.111 
The amended regulations would also permit generic drugs 
which no longer have a brand-name counterpart to update their 
own labels.112  Under current regulations, there is no technique to 
accomplish such label change, and therefore, these drugs are being 
sold on the market with potentially incorrect or out-of-date safety 
information.113  The FDA estimates approximately 420 drugs are 
sold only in the generic form, and the listed drug is no longer 
manufactured.114  Current FDA regulations also prohibit a generic 
drug manufacturer from sending a “Dear Doctor” letter which 
would inform physicians of updated and new safety warning 
information.115  The FDA views “Dear Doctor” letters as labeling, 
therefore a generic is not permitted to send such letter with new 
safety information that is different from the brand name label.116 
III. REEXAMINING THE CURRENT FDA REGULATIONS TO PERMIT GENERIC 
DRUG MANUFACTURERS TO UPDATE SAFETY LABELS 
FDA-approved drug labeling provides patients with essential 
information needed for the safe and effective use of a drug.  Further, 
approved labels reflect the FDA’s findings of the safety and 
effectiveness under the labeled conditions of use.117  Scholars argue 
that “[t]he primary purpose of labeling for prescription drugs is to 
 
 109  Id. 
 110  Press Release, U.S. Food and Drug Administration, FDA Takes Action To Speed 
Safety Information Updates on Generic Drugs (Nov. 8, 2013) 
http://fda.gov/newsevents/newsroom/pressannouncements/ucm374171.htm. 
 111  Woodcock, supra note 15. 
 112  Carlson, supra note 10. 
 113  Carlson, supra note 10. 
 114  Allison Zieve, Guaranteeing Patient Safety, U.S. NEWS,Sept. 22, 2014, 
http://www.usnews.com/opinion/articles/2014/03/27/fdas-generic-drug-lableing-
proposal-guarantees-patient-safety. 
 115  Boyd, supra note 65 at 1536. 
 116  Id. 
 117  Supplemental Applications Proposing Labeling Changes for Approved Drugs 
and Biological Products, supra note 30. 
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provide health care practitioners with the essential scientific 
information needed to facilitate prescribing decisions, thereby 
enhancing the safe and effective use of prescription drug products 
and reducing the likelihood of medication errors.”118  This safety 
information is used by practitioners and patients to make decisions 
about prescription drugs by weighing the stated risks against the 
benefits.119 
As of 2010, nearly 90% of pharmaceuticals in the United States 
are filled with a generic brand despite the availability of a 
substitute.120  Despite the changes in the market, and the evolution 
of the generic drug industry, the regulations concerning generic 
labeling have remained largely unchanged.121 
Generic drug makers may not always be able to quickly inform 
consumers of updated safety information, because they are not able 
to act under the same authority as their brand-name counterparts.122  
Generic drugs must maintain an identical label to their brand-name 
substitutes, and are only required to update safety labels when the 
brand-name has filed a CBE Supplement with the FDA and the 
change has been approved.123 
A. Public Policy Favors Informing Patients and Physicians of 
Changes in Drug Safety Information 
The side effects and risks of taking a particular drug may not 
come to light until after the drug has been approved by the FDA.124  
Therefore, both brand-name and generic makers are required to 
have written procedures for the review, surveillance and reporting 
of adverse drug information, and any “serious and unexpected” drug 
experiences to the FDA.125  Information obtained from any source, 
foreign or domestic, or any type of post-marketing study or 
 
 118  Supplemental Applications Proposing Labeling Changes for Approved Drugs 
and Biological Products, supra note 30. 
 119  Supplemental Applications Proposing Labeling Changes for Approved Drugs 
and Biological Products, supra note 30. 
 120  HHS, ASPE Issue Brief: Expanding the Use of Generic Drugs, (Sept. 22, 2014), 
available at http://aspe.hhs.gov/sp/reports/2010/genericdrugs/ib.shtml. 
 121  Wolfe, Sidney M, Allison M. Zieve & Brian Wolfman.  Citizen Petition (Aug. 29, 
2011). 
 122  Silverman, How Fast Should a Generic Drug Maker Update Labeling with New Safety 
Info?, supra note 14. 
 123  Supplemental Applications Proposing Labeling Changes for Approved Drugs 
and Biological Products, supra note 30. 
 124  Boyd, supra note 65 at 1535. 
 125  21 C.F.R. § 312.32(c)(1)(i). 
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investigation must be reviewed.126  Both brand-name and generic 
manufacturers must comply with postmarking reports by 
submitting an annual report to the FDA including a summary of 
information that may affect the drug’s safety, effectiveness, or 
labeling, as well as a description of the actions taken in response to 
the new information and proposed revisions to the safety labels.127 
The Supreme Court ruling in PLIVA sparked the concern that 
generic labels are not sufficient to warn consumers of the risks 
associated with medications.128  Public policy favors informing 
health care practitioners and patients of prescription medication 
safety information.  The public will benefit as a result of 
manufacturers updating drug safety labels in response to newly 
acquired safety information.129  Allison Zieve, head of the litigation 
group at Public Citizen, commented “[n]o drug is safe in all 
situations. A drug is safe when used in accordance with labeling that 
accurately reflects the known risks.  The sooner generic drug 
companies are allowed to make safety updates, the better for public 
health.”130  The public is harmed when a regulatory delay allows a 
safety gap and when relevant information is not readily available to 
the affected parties.131  The ability to update safety information will 
ensures that patients have the most recent and reliable information 
about their medications, and can make an informed choice on 
whether to take a prescribed drug. 
The proposed amendments to current FDA regulation will 
permit generic drug makers to update product labeling to “reflect 
data obtained through post-market[ing] surveillance.”132  Although 
the proposed amendment does not require generic manufactures to 
conduct new clinical tests, it will allow the manufacturers to 
inexpensively update labels when adverse information is received 
and investigated, while still keeping prices lower than brand-name 
 
 126  Supplemental Applications Proposing Labeling Changes for Approved Drugs 
and Biological Products, supra note 30. 
 127  Id. 
 128  Ed Silverman, FDA Delays Final Rule on Allowing Generic Drug Makers to Update 
Labels, WSJ PHARMALOT, (Nov. 18, 2014), http://blogs.wsj.com/pharmalot/2014/11/18 
/fda-delays-final-rule-on-allowing-generic-drug-makers-to-update-labels/. 
 129  Woodcock, supra note 15. 
 130  Silverman, FDA Delays Final Rule on Allowing Generic Drug Makers to Update 
Labels, supra note 128.  
 131  Silverman, FDA Delays Final Rule on Allowing Generic Drug Makers to Update 
Labels, supra note 128 
 132  Woodcock, supra note 15. 
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counterparts.133  Some argue prices will increase due to the liability 
generic drug makers would face.134  However, proponents believe 
generic drug makers will not face an increase in litigation because 
lawsuits would be less likely to occur when generic drugs are able to 
update safety information, preventing injury from occurring 
altogether.135  The FDA states the proposed regulation will “provide 
incentive to generic drug companies to actively participate with the 
FDA in ensuring the timeliness, accuracy and completeness of drug 
safety labeling.”136 
Lawmakers believe that”[t]his proposal will help equip health 
care providers and consumers who depend on generic drugs with 
the best possible information to avoid adverse outcomes.”137  The 
public will benefit because both brand-name and generic drug 
manufacturers will have the obligation to give doctors and patients 
the information necessary to avoid injuries.138  Through this 
amendment, the FDA will not only be able to preserve the principal 
of “sameness” between brand-name and generic drugs, but will also 
allow patients to have better information about a drug’s potential 
risks and benefits, regardless of the manufacturer.139 
Many opponents of the regulations claim that the time period 
where labels may differ will cause confusion and lead to over-
warning.140  However, under the current regulations, when a brand-
name drug has a safety label update, it can take several months 
before generic drug manufacturers update their labels with the new 
warnings.141  Also, brand-name drugs have possessed the ability to 
update their own safety labels for over thirty years, and there has 
never been a problem with over-warning of safety information.142 
 
 133  See generally note 41. 
 134  Toni Clarke, FDA defends generic drug label proposal at U.S. House hearing, REUTERS, 
April 1, 2014, http://www.reuters.com/article/2014/04/01/generic 
drugs-idUSL1N0MT1IV20140401. 
 135  Id. 
 136  Peter C. Neger, FDA Proposes New Change to Generic Labeling Rule, 
MARTINDALE.COM (Nov. 13, 2013), http://www.martindale.com/ products-liability-
law/article_Bingham-McCutchen-LLP_2028576.htm. 
 137  Press Release, U.S. Senate Committee on Health, Education, Labor, & Pensions, 
Harkin Welcomes FDA’s Release of Proposed Rules to Protect Consumers Using 
Generic Drugs (Nov. 8, 2013), available at http://www.help.senate.gov/newsroom 
/press/release/?id=fdadb26d-2999-4a09-9766-a2a2f7546701. 
 138  Id.  
 139  Id. 
 140 Zieve, supra note 114. 
 141  Zieve, supra note 114. 
 142  Zieve, supra note 114. 
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The confusion concerning the temporary differences in brand 
and generic labels will be outweighed by the public health 
benefits.143  Dr. Woodcock, opined: “It is expected that a valid safety 
concern regarding a generic drug product also would generally 
warrant submission of a supplement for change to the labeling by 
the application holder for the corresponding brand drug, as well as 
other generic drug application holders.”144  Therefore, it can be 
assumed when new safety information is acquired, all 
manufacturers will apply to change the label, reducing the amount 
of differing labels even before the FDA has approved the change.  
Further, the FDA will maintain a website tracking CBE-0 
supplements, so health care providers and patients will have access 
to the newest changes and updates.  Once the FDA approves a CBE-
0 supplement, it will continue to be posted on the site, and a thirty-
day timeframe will be established for drug manufacturers to submit 
a CBE-0 supplement conforming to the label change.145  This will 
cut down the amount of time that differing labels will be available 
on the market.146  Under the FDCA, the FDA is authorized to 
“require and, if necessary [order] labeling changes if the FDA 
becomes aware of new safety information that the FDA believes 
should be included in the labeling of the drug.”147  Therefore, the 
FDA can implement a rule allowing generic drugs to independently 
update warning labels, ensuring the newest warnings are available 
to consumers, regardless of whether they take brand-name or 
generic medication. 
Senator Henry Waxman, co-author of the 1984 Hatch-Waxman 
Act, argued that allowing generic drugs to update their labels will 
ease customers’ concerns about the danger of taking generic drugs 
because they will be aware of the latest risks and safety information.  
Waxman further argued that it will aid in preventing consumers 
from believing generic drugs are not as safe as brand-name drugs 
because generics will have more incentive to warn consumers about 
safety issues, and will be able to get the information out to 
consumers.148  Generic drug manufacturers have already proven that 
 
 143  See Zieve, supra note 114. 
 144  Woodcock, supra note 15. 
 145  Woodcock, supra note 15, at 7. 
 146  Woodcock, supra note 15, at 7, 9. 
 147  U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY: SAFETY LABELING CHANGES- 
IMPLEMENTATION OF SECTION 505(O)(4) OF THE FD&C ACT, 3 (2013), available at 
http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/gui
dances/ucm250783.pdf. 
 148  Tim Devaney, FDA Raises Safety Measure for Generic Drugs. THE HILL, April 1, 
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generic drugs are equally as safe as the brand-name counterpart and 
the FDA has agreed.149  Gary Beuhler, Director of the FDA’s office of 
Generic Drugs argued “[m]ost people believe that if something costs 
more, it has to be better quality.  In the case of generic drugs, this is 
not true . . . [t]he standards for quality are the same for brand-name 
and generic products.”150 
Alison Zieve of Public Citizen has argued, “[a]s generic drugs’ 
market shares increase, brand-name drugs lose incentive to engage 
in safety monitoring.”151  Zieve further argued “[t]he FDA cannot 
monitor all post-approval data by itself, drug safety is threatened 
when the regulatory and common-law incentives designed to 
motivate manufacturer diligence weaken with shifting control of 
market share.”152  Because the generic drug has the majority of the 
market share, they will probably receive the most reports concerning 
risks and adverse experiences using the drug.153  Generic 
manufacturers therefore may be in a better position to update 
product safety labels because they serve a larger amount of the 
population.154  Under the current system, the generic manufacturers 
cannot update safety information until the brand-name takes 
action.155 
Allowing generic drug manufacturers to independently update 
product safety labels in light of newly acquired safety information 
will be a great benefit to public health by increasing patient safety 
and awareness, while keeping costs and confusion at a minimum. 
B. Generic Drugs Will Continue to be an Affordable Alternative to 
Brand-Name Prescriptions 
Generic drugs are more affordable because manufacturers do 
 
2014, http://thehill.com/regulation/healthcare/202383-fda-raises-safety-measures-
for-generic-drugs. 
 149  FDA Ensures Equivalence of Generic Drugs, U.S. FOOD & DRUG ADMIN. (Aug., 
2002), 
http://www.fda.gov/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparednes
s/ucm134444.htm (quoting Gary Beuhler, Director of FDA’s Office of Generic Drugs). 
 150  Id. 
 151  PUBLIC CITIZEN, GENERIC DRUG LABELING, 24 (2013), available at 
https://www.citizen.org/documents/2138.pdf.  
 152  Examining Concerns Regarding FDA’s Proposed Changes to Drug Labeling: Hearing 
Before the Comm. on Energy and Commerce, 113th Cong. 7 (2014), (statement of Allison 
Zieve, Director, Public Citizen Litigation Group). 
 153  Id. 
 154  Id. 
 155  See Supplemental Applications Proposing Labeling Changes for Approved 
Drugs and Biological Products, 78 Fed. Reg. 67985 (proposed Nov. 13, 2013). 
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not need to spend money on costly clinical trials.  Even if generics 
had more responsibility under the proposed regulation, the savings 
would still be apparent.156  The proposed rule would assist in 
keeping liability costs down by preventing injuries from occurring 
in the first place through efficient safety label updates.157  Currently, 
generic drugs are shielded from liability because they cannot update 
their labels.  If a generic drug maker becomes aware of a risk, they 
cannot change safety labels, unless the brand-name does so. 
Critics of the proposed regulation fear that allowing generic 
drug makers to update their product safety labels will open them up 
to failure-to-warn lawsuits.158  However, if the injuries had never 
occurred, there would be no lawsuit.159  Allison Zieve of Public 
Citizen testified in front of the House of Representatives 
Subcommittee on Health: 
Because immunizing the companies from liability does not make the 
injured patients’ costs go away.  The medical expenses and lost wages 
from lost work time still exist; they are carried by the patients, health 
insurers, and taxpayers, through Medicare or Medicaid.  Because the 
proposed rule will give generic manufacturers the tools and incentive to 
update safety labeling, any costs of the rule should be offset by cost 
savings—savings in medical care for the patients who will not be injured 
because physicians and patients are armed with updated labeling about 
safety risks.160 
Critics also fear that generic drug manufacturers may over-warn 
to avoid liability.  However, proponents have noted since the ruling 
in Wyeth there has not been a surge in CBE-0 supplements to update 
brand-name labels, therefore there should not be a worry for over 
warning by generic drug makers.161 
According to the FDA, “the main reason generic drug 
companies can market their drugs at lower prices is that they don’t 
face the same development costs as brand-name companies.”162  
Generic drugs are approved through an expedited process, and are 
permitted to skip costly clinical trials provided that the drug is the 
“same” and the “bioequivalent” of its brand-name counterpart.163  
 
 156  Boyd, supra note 65, at 1539. 
 157  Zieve, supra note 114.  
 158  Friedman, supra note 18, at 3. 
 159  Friedman, supra note 18, at 10. 
 160  Examining Concerns Regarding FDA’s Proposed Changes to Drug Labeling: Hearing 
Before the Comm. On Energy and Commerce, supra note 152.  
 161  Boyd, supra note 65 at 1543-44. 
 162  Michelle Meadows. New FDA Initiatives to Improve Drug Reviews and Reduce Legal 
Loopholes, U.S. FOOD & DRUG ADMIN. (Sept./Oct. 2003), http://www.fda.gov/Drugs/ 
ResourcesForYou/ucm134448.htm. 
 163  Neas, supra note 3. 
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The proposed regulation does not place any new requirements for 
generic drugs to undergo separate clinical trials and testing, 
therefore the costs to consumers should remain low.164  Allison 
Zieve stated “[g]eneric competition [also] helps keep the cost of 
drugs down . . . it also encourages the research based drug 
companies to keep finding new and better medicines that have 
patent protection.”165 
An estimate published by the consulting firm Matrix Global 
Advisors stated the proposed rule would lead to approximately a five 
percent annual increase in spending on generic drugs.166  The FDA 
has examined the economic impacts of the proposed regulation and 
has determined: 
the proposed rule would only impose new burdens on small generic drug 
manufacturers who submit CBE-0 supplements for safety-related 
labeling changes.  The FDA believes the impact will not be significant 
due to the low cost of submission, and the uncertainty of the amount of 
supplements that may be filed.167 
C. Allowing Generic Drug Makers to Update Product Safety Labels 
will Provide a Means for Generic Drugs which no Longer have 
a Brand-name Counterpart to Make Safety Updates 
The FDA estimates there is approximately 420 drugs that are 
sold only in the generic form.168  The Generic Pharmaceuticals 
Association states that number is even larger, estimating that about 
45% of generic drugs have no brand-name counterpart.169  There is 
a gap in the current regulatory system for generic drugs whose 
brand-name drug counterpart is no longer sold on the market.  Since 
a brand-name drug is only permitted to update safety warnings on 
product labels, the generic drugs that no longer have a brand-name 
counterpart are left without a means of updating safety label 
information.170  Currently, there are no clear and efficient methods 
to disseminate information to health care providers, and the public, 
about newly discovered safety risks.171 
 
 
 
 164  See generally, Devany, supra note 148. 
 165  Devany, supra note 148 
 166  Carlson, supra note 10.  
 167  Wolfman, supra note 23. 
 168  Zieve, supra note 114. 
 169  Zieve, supra note 114. 
 170  Boyd, supra note 65. 
 171  Carlson, supra note 10. 
SEIDEN_FINAL_FORMAT.DOCX (DO NOT DELETE) 8/23/2016  11:16 PM 
432 SETON HALL LEGISLATIVE JOURNAL [Vol. 40:2 
This is concerning because serious drug risks may not be 
identified until after the generic drug enters the market, and several 
generic drugs no longer have a corresponding brand-name drug on 
the market.172  Without a corresponding brand-name drug, there are 
no available resources to conduct ongoing investigations as to the 
safety of the drug.173  Therefore, drugs that are only available in 
generic form are not continuously monitored or investigated, and 
there is no way to update the drug’s label if new safety information 
comes to their attention. 
IV. CONCLUSION 
The FDA has acknowledged the growth of the generic 
pharmaceutical industry, and its impact on the United States’ health 
industry.  Today, generic drugs fill almost 90% of all 
pharmaceuticals in the United States, yet consume only 27% of total 
drug spending, resulting in huge savings to American consumers 
every year.174 
The Hatch-Waxman Act of 1984 allowed generic drugs to be 
approved through an abbreviated process, provided the generic drug 
was the “same” in ingredients, dosage, and administration, and was 
the “bioequivalent” of the brand-name drug.175  The enactment led 
to a greater number of generic drug approvals, and millions of 
dollars of savings in drug costs to American consumers.176 
The FDASIA and GDUFA were enacted in 2012 in response to 
the emerging generic drug industry.177  The GDUFA was enacted to 
increase safety and accessibility of generic drugs, and provide 
transparency by inspecting all generic drug facilities.178  The Act was 
designed to expedite the approval process of generic drugs, and as a 
result, cut down the backlog of pending approvals.179  As generic 
 
 172  Carlson, supra note 10. 
 173  Carlson, supra note 10. 
 174  Neas, supra note 3. 
 175  Wolfman, supra note 23. 
 176  Generic Drug User Fee Act Program Performance Goals and Procedures, supra note 
43. 
 177  Fact Sheet: New User Fees for Generic Drugs Will Enhance American’s Access to 
Less Expensive Drugs and Generate Major Cost Savings, http://www.fda.gov/ 
RegulatoryInformation/Legislation/SignificantAmendmentstotheFDCAct/FDASIA/uc
m310992.htm (last visited Mar.. 24, 2016). 
 178  Supplemental Applications Proposing Labeling Changes for Approved Drugs 
and Biological Products, supra note 30. 
 179  Gil Y. Roth, Generic Manufacturing: GDUFA & CMOs, CONTRACT PHARMA, (Nov. 
12, 2014), http://www.contractpharma.com/issues/2013-03/view_features/generic-
manufacturing-gdufa-cmos/.  
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drugs continue to take an increasing amount of market share, the 
government has responded by imposing similar burdens and 
benefits on generics as brand-name drugs through GDUFA.  
Allowing generic drugs to file CBE-0 changes and update labels 
would conform to this emerging trend. 
The proposed regulation to permit generic drug manufacturers 
to update their safety labels without FDA approval, and 
independent of the brand-name drug’s label will result in an 
increase of safety information that is beneficial to public health.  
Patients and physicians will be up to date with the newest safety 
information concerning generic drugs, which are used by the 
majority of Americans today. 
Although this may create temporary differences between 
generic and brand-name drug labels, it will increase patient safety 
overall.  Allowing generic drug manufacturers to independently 
update safety labels will also encourage them to monitor and 
research the safety of marketed drugs; while also having the 
possibility of increasing the quality of the drugs being manufactured 
by creating liability for generic products. 
Updating the FDA’s current regulations will also create an 
opportunity for generic drugs that no longer have a brand-name 
counterpart to keep patients up to date on the newest safety 
information, and provide a consistent method for updating safety 
labels for all drugs and prescriptions in the United States. 
 
